Aminoglycoside Antibiotic
Gentamicin Sulfate for Epidermolysis Bullosa
Recruiting3 awardsPhase 1 & 2
Los Angeles, California
This trial will test if gentamicin can be used to treat Herlitz junctional epidermolysis bullosa (H-JEB), an incurable skin disease, by restoring laminin 332 assembly and improving wound closure.
Antimicrobial Wound Cleansing Spray
Antimicrobial Wound Cleansing Spray for Epidermolysis Bullosa
Recruiting1 awardPhase < 1
Chicago, Illinois
This trial tests a special spray to clean and heal infected wounds in patients with a rare skin condition. The spray aims to reduce harmful bacteria, helping the wounds heal better.
Popular Filters
Trials for EB Patients
Mesenchymal Stromal Cells
Stem Cell Therapy for Epidermolysis Bullosa
Recruiting1 awardPhase 3
Minneapolis, Minnesota
This trial is testing a special cell therapy given through an IV to people with a severe genetic skin condition called RDEB. The therapy aims to help heal and grow new, healthy skin. Researchers are evaluating its safety and effectiveness. Previous tests have shown increased collagen expression and faster wound healing in patients with RDEB.
Gene Therapy
FCX-007 for Epidermolysis Bullosa
Recruiting2 awardsPhase 3
Stanford, California
This trial tests if FCX-007 can improve wound healing in people with RDEB, a condition causing persistent wounds. FCX-007 is injected into the skin to help it heal by providing missing elements. The study observes how treated wounds heal compared to other wounds in the same patients. FCX-007 is a gene therapy designed to deliver COL7A1 to the skin, aiming to restore collagen VII expression and improve wound healing in RDEB patients.
Small Molecule
Rigosertib for Skin Cancer in Dystrophic Epidermolysis Bullosa
Recruiting1 awardPhase < 1
Philadelphia, Pennsylvania
This trial studies how rigosertib sodium, a drug taken orally or through IV, can help treat patients with a rare skin condition and advanced skin cancer who haven't responded to other treatments. The drug targets and kills cancer cells while leaving healthy cells alone. Rigosertib has shown potential as a therapeutic option for nonresectable cholangiocarcinoma, demonstrating antitumoral and radiosensitizing effects.
Trials for COL7A1 Positive Patients
Mesenchymal Stromal Cells
Stem Cell Therapy for Epidermolysis Bullosa
Recruiting1 awardPhase 3
Minneapolis, Minnesota
This trial is testing a special cell therapy given through an IV to people with a severe genetic skin condition called RDEB. The therapy aims to help heal and grow new, healthy skin. Researchers are evaluating its safety and effectiveness. Previous tests have shown increased collagen expression and faster wound healing in patients with RDEB.
Gene Therapy
FCX-007 for Epidermolysis Bullosa
Recruiting2 awardsPhase 3
Stanford, California
This trial tests if FCX-007 can improve wound healing in people with RDEB, a condition causing persistent wounds. FCX-007 is injected into the skin to help it heal by providing missing elements. The study observes how treated wounds heal compared to other wounds in the same patients. FCX-007 is a gene therapy designed to deliver COL7A1 to the skin, aiming to restore collagen VII expression and improve wound healing in RDEB patients.
Trials With No Placebo
Gene Therapy
FCX-007 for Epidermolysis Bullosa
Recruiting2 awardsPhase 3
Stanford, California
This trial tests if FCX-007 can improve wound healing in people with RDEB, a condition causing persistent wounds. FCX-007 is injected into the skin to help it heal by providing missing elements. The study observes how treated wounds heal compared to other wounds in the same patients. FCX-007 is a gene therapy designed to deliver COL7A1 to the skin, aiming to restore collagen VII expression and improve wound healing in RDEB patients.
Small Molecule
Rigosertib for Skin Cancer in Dystrophic Epidermolysis Bullosa
Recruiting1 awardPhase < 1
Philadelphia, Pennsylvania
This trial studies how rigosertib sodium, a drug taken orally or through IV, can help treat patients with a rare skin condition and advanced skin cancer who haven't responded to other treatments. The drug targets and kills cancer cells while leaving healthy cells alone. Rigosertib has shown potential as a therapeutic option for nonresectable cholangiocarcinoma, demonstrating antitumoral and radiosensitizing effects.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.